THE USPTO GRANTS CYTOREX US PATENT NO. 7,141,251 ON IT'S ANTI-CANCER DRUGS CYTOREG® & CYTOREGUNO (TM)

SOUTH FLORIDA BUSINESS JOURNAL :  (3 to 9 February 2006):  "Cancer Drug takes an unconventional route"
 

Welcome


 Version en Español - Intro
 

Research Reports:
 

Journal of Carcinogenesis (2006):

Cytoreg® inhibits growth and proliferation of human adenocarcinoma cells via induction of apoptosis
 
 

Society of Toxicology Annual Meeting (New Orleans, 2005), Poster/Abstract:

Evaluation of Cytoreg® Using In Vitro Toxicity Screening in Rat Hepatoma (H4IIE) Cells, Normal Rat Kidney (NRK) Cells, and Rat Primary Hepatocytes
 
 

Drug Discovery Technology Conference (Boston, 2004), Poster/Abstract:

Effect of Cytoreg® on Biomarkers in B16-F10 Murine Melanoma
 
Acrobat Reader must be installed to read these documents
 

 

Disclaimer

This website is intended for informational purposes only. Nothing in this website is intended, or should be understood to make claims regarding the safety or efficiency of any treatments. Unless otherwise indicated, none of the statements in this website have been reviewed or approved by the United States FDA,  or by any other international drug approving agency.  Always consult qualified health care providers for advice about any medical condition or concern.
 

  
You must have installed Flash player 7 to see this page correctly

© 2007 Cytorex Biosciences, Inc.

Cytorex Biosciences, Inc.
4474 Weston Road  No. 108, Weston, FL 33331
Voice: 954-937-8519| Fax: 954-337-2249
info@cytorex.com